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Introduction
Measures that allow the severity of respiratory disease to be quantified accurately are essential for optimal patient management. The majority of assessment techniques in current use examine a single component of respiratory function, such as airflow obstruction or lung volumes. Measurement of neural respiratory drive (NRD), obtained from respiratory muscle electromyography, provides an index of the overall load on the respiratory system and represents a promising method for assessment of the severity of lung disease.
The pathophysiological changes that occur in obstructive lung diseases adversely influence the loadcapacity balance of the respiratory muscle pump. Elevated airway resistance, together with distal airway collapse and gas trapping that result in intrinsic positive end-expiratory pressure, all impose loads on the respiratory muscles during inspiration. Additionally, increases in end-expiratory lung volume result in respiratory muscle shortening and mechanical disadvantage, reducing their force-generating capacity and leading to functional weakness ). In the face of such changes in load and capacity, compensatory increases in NRD occur to maintain ventilation at an appropriate level for blood gas homeostasis.
Studies in patients with moderate-to-severe lung disease have demonstrated strong relationships between NRD and the extent of both airflow obstruction and hyperinflation Reilly et al. 2011) . The relative influence of the two factors has not, however, been described. Reilly et al. (2011) reported progressive increases in NRD, measured using both the diaphragm EMG and parasternal intercostal electromyogram (EMGpara), during incremental exercise in patients with cystic fibrosis and matched healthy control subjects. The patients demonstrated exercise-induced dynamic hyperinflation, but the relative influence of such changes in end-expiratory lung volume over and above that imposed by airway resistance and the metabolic load of the exercise was not described.
Airway challenge testing allows stepwise decrements in pulmonary function to be induced in controlled circumstances. Bronchoconstriction is the primary change that occurs during airway challenge testing, although hyperinflation may also occur in some individuals (American Thoracic Society, 2000) . Airway challenge testing provides a model by which the changes in NRD resulting from acute, stepwise changes in pulmonary function can be assessed without the confounding influences that may be encountered in a longitudinal study in patients with lung disease, such as the metabolic influences of infection or changes in medication.
The aims of this study were, therefore, to investigate the changes in EMGpara induced by airway challenge testing and to determine the relative independent contributions of bronchoconstriction and increased end-expiratory lung volume. We hypothesized that EMGpara would increase in relationship to the degree of bronchoconstriction and that hyperinflation would exert a further influence on changes in EMGpara.
Methods
Ethical approval for the study was granted by the King's College Hospital Research Ethics Committee (reference number 09/H0808/100). All subjects gave written informed consent for participation in the study. All ethical aspects of the experiments conformed to the Declaration of Helsinki.
Subjects
Thirty-two subjects with a self-reported history of atopy, asthma or known bronchial hyper-responsiveness were studied. The median (interquartile range) age of the group was 29.2 (24.3-33.5) years. All subjects had spirometry within normal limits at baseline.
Anthropometry
Height was measured using a wall-mounted stadiometer (Harpenden, Holtain Ltd, Crymych, UK) with a resolution of 1 mm (range 600-1200 mm). The subject was asked to remove footwear and stand upright with heels, back and occiput against the stadiometer. A 1 kg weight was placed on the stadiometer carriage to improve accuracy.
Weight was measured using an electronic medical scale (HR Person Scale; Marsden Ltd, Henley on Thames, UK) with a resolution of 0.05 kg and a maximal weighing capacity of 300 kg. The subject was asked to remove footwear and any heavy clothing and remain stationary on the scale until a steady reading was obtained. Respiratory muscle EMG in methacholine challenge
Parasternal intercostal electromyography
Skin was prepared in accordance with international guidelines for EMG recording (Hermans et al. 2000) . Initially, the skin was scrubbed with an abrasive gel (Nuprep; Weaver and Company, Aurora, CO, USA) to remove dead skin cells and excessive sebum in order to minimize electrode-skin impedance. Any remaining gel and sebum was then removed with an alcohol-impregnated wipe before self-adhesive silversilver chloride electrodes were applied (Kendall Arbo, Tyco Healthcare, Neustadt/Donau, Germany). Electrodes were applied in the second intercostal space bilaterally, 3 cm lateral to the sternum, with a reference electrode placed on the acromion process of the scapula.
Signals were amplified and bandpass filtered between 10 and 3000 Hz, with an additional analog notch filter at 50 Hz to minimize mains frequency interference, using a PClab 3808 Biomedical Amplifier (Yinghui Medical Technology Co. Ltd, Guangzhou, China). EMG signals were acquired (PowerLab 16SP; ADInstruments, Sydney, NSW, Australia) and displayed on a laptop computer (MacBook Pro; Apple, Cupertino, CA, USA) running LabChart software (Version 7.2; ADInstruments Pty, Colorado Springs, CO, USA) with analog-to-digital sampling at 10 kHz. Both the amplifier and the analog-to-digital convertor were earthed to suitable points in the laboratory. An additional 20 Hz postacquisition digital high-pass filter was applied via the LabChart software to assist in the removal of ECG artefact. Data were displayed as both raw EMG and as a root mean square (RMS) trace, using a moving average window of 50 ms (Ives & Wigglesworth, 2003) .
The EMGpara was recorded during tidal breathing. Subjects were seated upright in a chair with back supported, arms placed on armrests and feet flat on the floor to minimize trunk postural activity. Subjects were instructed to remain still and not to speak throughout the recording period.
Parasternal intercostal EMG activity, occurring between QRS complexes, was highlighted and the peak RMS EMGpara calculated. The mean peak RMS EMGpara per breath was calculated over the final minute of each recording period.
Spirometry
Spirometry was performed in accordance with American Thoracic Society/European Respiratory Society criteria (Miller et al. 2005 ) using a portable electronic spirometer (KoKo spirometer; Ferraris Respiratory, Louisville, CO, USA). The correct technique was explained and demonstrated to each subject before testing. The subject was seated upright with head and neck in a neutral or slightly extended position, fitted with a nose-clip and asked to seal their lips tightly around a flanged mouthpiece. The subject was then asked to inspire rapidly and fully to total lung capacity and then, after a pause of no more than 1 s, to perform a maximal forceful exhalation and to maintain expiratory flow until no more air could be expelled. Subjects were encouraged to 'blast' rather than 'blow' the air from the lungs, and strong verbal encouragement was given throughout each manoeuvre to promote complete exhalation. Any traces showing evidence of incomplete exhalation, glottic closure, cough or air leak were rejected. Repeated efforts were performed at baseline until three acceptable manoeuvres were obtained. Acceptable repeatability was considered to have been obtained when the difference between the largest and second-largest values was <150 ml or 5%. Values for forced expiratory volume in 1 s (FEV 1 ) and forced vital capacity were expressed as a percentage of predicted values (Quanjer et al. 1993) .
Methacholine challenge testing
The methacholine challenge test was performed in accordance with international guidelines (American Thoracic Society, 2000) . Testing was performed in a well-ventilated room. Subjects were seated in a chair suitable for EMG recording, and baseline pulmonary function testing was performed as described.
The methacholine challenge was performed using a dosimeter (KoKo USB digidoser; Ferraris Respiratory) and nebulizer (DeVilbiss 646 characterised nebuliser; Ferraris Respiratory) with a certified output of 1.134 ml min −1 . Subjects were required to wear a nose-clip and inhale and exhale through the mouthpiece at a maximal flow of 0.5 l s −1 imposed by a flow restrictor. Use of a dosimeter and flow restrictor improve the accuracy and repeatability of the dose delivered (American Thoracic Society, 2000) . Inspiratory and expiratory duration were also fixed at 5 s using auditory prompts. Subjects were given verbal encouragement to maintain respiratory flow at the required rate and for a sufficient duration.
Measurement of respiratory flow and volume
Respiratory flow was measured using a pneumotachograph (range 0-800 l min −1 , model 4813; Hans Rudolph Inc., Kansas City, KS, USA) attached to a flanged mouthpiece, with the subject wearing a nose-clip. Differential pressure across the pneumotachograph was measured using a pressure transducer (MP45-16; Validyne, Northridge, CA, USA). The signal from the transducer was amplified (CD280; Validyne), and recorded and displayed alongside EMGpara by the acquisition software (LabChart) with analog-to-digital sampling of 100 Hz (PowerLab 16SP). Volume was measured via digital integration of the flow signal using LabChart software.
V. MacBean and others
Inspiratory capacity (IC) was obtained by asking the subject to perform a slow maximal inhalation to total lung capacity from functional residual capacity. This was repeated three times, each effort interspersed with three to five tidal breaths, and the mean of the three efforts recorded. Significant hyperinflation was defined as a decrease in IC of ࣙ300 ml (Lougheed et al. 2006) .
Protocol
All testing was performed on a single occasion. Participants were requested to refrain from taking short-acting β 2 agonists or antihistamine medication and from consuming products containing caffeine (coffee, tea, cola or chocolate) on the day of testing. Subjects were familiarized with study instrumentation and the protocol was explained in detail. Anthropometric and demographic data were recorded and baseline spirometry was performed. The five-breath dosimeter protocol was used, with an initial diluent step using 0.9% saline followed by methacholine concentrations of 0.0625, 0.25, 1, 4, 8, 16 and 32 mg ml −1 (Acetyl-B-Methyl Choline; Nova Laboratories, Wigston, UK). Doses were delivered at 5 min intervals. At the beginning of testing, the diluent was administered via the digidoser and a single technically acceptable FEV 1 manoeuvre performed at 30 and 90 s after dose delivery and the lower of the two values used. After the second forced expiratory manoeuvre, three IC manoeuvres were performed and EMGpara was then recorded during tidal breathing for the remaining 3 min until delivery of the next dose. The protocol was repeated, using increasing doses of methacholine, until the subject's FEV 1 had decreased by 20% or more from the postdiluent value or until the maximal methacholine dose had been delivered. If a ࣙ20% reduction in FEV 1 was elicited, the test was discontinued and bronchoconstriction reversed through the administration of 400 μg salbutamol.
The PC20 is defined as the provocative concentration of methacholine inducing a 20% reduction in FEV 1 , and was calculated using the following formula:
where C 1 is the penultimate methacholine concentration, C 2 the final methacholine concentration, R 1 the percentage reduction from postdiluent stage in FEV 1 after C 1 , and R 2 the percentage reduction from postdiluent stage in FEV 1 after C 2 .
Statistical analysis
Differences in EMGpara, FEV 1 and IC from baseline (measurements made postdiluent step) to end of test were assessed using Wilcoxon's matched pairs test. Differences between the groups of subjects in whom significant hyperinflation was and was not observed were assessed using the Mann-Whitney U test. Linear mixed model analysis was then used to analyse dose-wise changes in both FEV 1 and EMGpara, and thereafter to determine the independent influences of changes in FEV 1 and IC on the change in EMGpara. Models were also fitted to determine the trajectories of EMGpara between the hyperinflating and non-hyperinflating groups. Linear mixed model analysis is an extension of multiple regression, allowing irregularly spaced serial data for individuals to be combined in a single linear regression model, providing estimates of both longitudinal individual changes and group patterns (West, 2009) .
Fixed effects in the model were methacholine dose and FEV 1 when examining the entire cohort, with further models constructed incorporating IC both as a continuous variable and as a binary term (change in IC >300 or <300 ml). Random effect variables in all models were methacholine dose and an intercept term.
Models were estimated using restricted maximum likelihood, with all models centred on the diluent dose such that the intercept terms would be interpretable as the mean value of the dependent variable at commencement of testing, and slope would represent the change in the dependent variable per dose. Model fit to dose as linear and quadratic functions was evaluated because of the quadrupling/doubling dose protocol used and the known sigmoidal shape of the conventional FEV 1 dose-response curve (American Thoracic Society, 2000) . The selection of an appropriate covariance structure for the residuals and the validity of the quadratic versus linear functions of methacholine dose were assessed by likelihood ratio testing based on the −2 restricted maximum likelihood log-likelihood difference between the original and modified models (West, 2009).
Results
Participant characteristics are shown in Table 1 . All 32 subjects underwent full methacholine challenge testing with measurements of spirometry and EMGpara. A subset of 20 individuals had additional measurement of inspiratory capacity (termed the 'IC subgroup').
Of the 32 participants, 25 exhibited a clinically significant response to methacholine, defined as a decrease of ࣙ20% in FEV 1 . The median (interquartile range) change in FEV 1 was 27.8 (35.6-22.7)% in the responder subset and 7.2 (14.1-4.1)% in the non-responder group. All 20 subjects in the IC subgroup showed a clinically significant response, with a median (range) reduction in FEV 1 of 28.9 (37.0-22.8)%.
Significant changes were observed from baseline to end of test in FEV 1 and EMGpara in both the entire cohort and the 'responder' subset. The change in FEV 1 was significant in the non-responder group, but the change in EMGpara was not. Significant changes were observed in all parameters (FEV 1 , EMGpara and IC) in the IC subgroup of subjects. These results are summarized in Figs 1-3 and Table 2 .
Linear mixed model analysis demonstrated a significant positive interaction between a quadratic function for methacholine dose and change in EMGpara. There was an additional effect of the change in FEV 1 by dose on EMGpara, with the slope of the EMGpara versus dose 2 line increasing by 0.002 μV dose −2 (full cohort) or 0.003 μV dose −2 (Part B cohort) for each percentage of predicted decrease in FEV 1 . See Table 3 for full details of slopes and intercepts of these interactions. There was no significant effect of FEV 1 on the intercept of the EMGpara versus dose relationship, indicating no significant influence of baseline FEV 1 on pre-challenge EMGpara. Figure 4 shows the linear mixed model analysis-predicted EMGpara values plotted against measured FEV 1 .
Of the 20 participants undergoing measurement of IC, 10 demonstrated significant hyperinflation, defined as a decrease in IC of ࣙ300 ml (Lougheed et al. 2006 ). There were no differences in the characteristics of the subjects in the hyperinflating and non-hyperinflating groups, nor were there differences in the degree of bronchoconstriction or change in EMGpara at end of test between the hyperinflating and non-hyperinflating groups (Table 4) .
Inspection of the residuals from the model diagnostics derived from linear mixed model analysis showed that the IC data did not satisfy the assumption of homoscedasticity. The model was therefore reassessed after logarithmic transformation of the IC values. Linear mixed model analysis did not demonstrate a significant effect of the change in IC by dose on change in EMGpara, when treated either as a continuous variable (Table 5) or as a binary outcome (change in IC of >300 or <300 ml).
Discussion
This study has investigated in detail respiratory load compensation, using the change in parasternal intercostal muscle activity during chemical airway challenge, which has allowed investigation of the interaction between decrements in key pulmonary function parameters and the change in respiratory muscle activity. The hypothesis that EMGpara would increase in proportion with decrements in FEV 1 was supported; the secondary hypothesis, that hyperinflation would independently result in further increases in EMGpara, was refuted. These data suggest that during airway challenge testing bronchoconstriction imposes a greater relative load on the respiratory system, as indicated by increased neural drive to the parasternal intercostal muscles, than concomitant changes in end-expiratory lung volume. Maarsingh et al. (2002) examined the relationship between FEV 1 and respiratory muscle activity assessed using both parasternal intercostal and surface diaphragm EMG during histamine-induced bronchoconstriction in 15 asthmatic children. As with the present study, they observed a good agreement between the degree of airway narrowing and increases in EMG activity. Unlike the present study, however, the EMG data were expressed as the logarithm of the ratio of the EMG activity at each stage to that at baseline. This linear increase in the logarithmically transformed EMG data suggests that EMG activity in their study increased exponentially. Close agreement was also observed between the increase in EMG activity and decreases in FEV 1 expressed in 5% decrements from baseline, determined by linear interpolation. Expressing the data in this way, however, risks biasing the results towards a relationship. The linear mixed effects modelling used in the present study represents a more robust method for analysing data of this nature. Lavorini et al. (2013) also observed significant increases in EMGpara between baseline and end of test during methacholine-induced bronchoconstriction in 44 adults with mild asthma. No specific analysis was undertaken, however, of the relationships between airways obstruction (measured using the respiratory interrupter technique) and EMGpara.
Surface EMG of the second intercostal space can detect activity in nearby muscles, and close attention to the subjects' posture and upper limb movements is essential. Nearby large accessory muscles, such as pectoralis major, are, however, not normally recruited during tidal breathing. Postural influences on EMGpara activity have been reported (Hudson et al. 2010) , and we therefore ensured that subjects were well supported in the seated position to eliminate any contribution from postural activity. Subjects were also encouraged to refrain from any upper limb movements during recording periods, and EMG traces were carefully inspected to ensure absence of artefact. The EMGpara technique applied within the present study has previously been demonstrated to be reproducible and to agree with values obtained simultaneously using needle electrodes (Silver & Lehr, 1981) . International guidelines state surface respiratory EMG techniques to be of benefit in assessing the response to altered respiratory load, and to reflect changing neural output to the respiratory muscles (American Thoracic Society & European Respiratory Society, 2002) . Although airway challenge testing does not completely mirror the acute or progressive chronic pathophysiological changes that occur in obstructive lung disease, methacholine challenge testing is thought to reproduce the adverse mechanical consequences of a moderately severe asthma exacerbation (Pride & Macklem, 2011) and therefore represents a suitable model for the interpretation of changes in pulmonary function likely to be seen in asthmatic patients. Some studies examining end-expiratory lung volume changes during acute asthma exacerbations have, however, demonstrated somewhat greater hyperinflation (mean IC values ß50% lower) than was observed in the present study (Pretto et al. 2007; Azevedo et al. 2012) and, thus, the potential for heterogeneity in the pathophysiological changes between these different study settings must be recognized. Further exploration of the influence of hyperinflation and airflow obstruction within clinical populations would be of interest.
This is the first study to examine the independent relative contributions of airway obstruction and hyperinflation to respiratory load and NRD. Previous cross-sectional studies have demonstrated relationships between the severity of airflow obstruction (as quantified by FEV 1 ), measures of end-expiratory lung volume and levels of NRD measured using diaphragm EMG ) and/or EMGpara . These studies did not perform multivariate analyses to investigate the independent influence of each factor. In the present study, no effect of FEV 1 on the intercept of EMGpara was observed, suggesting no relationship between baseline levels of airway obstruction and NRD. This is not surprising, however, given the narrow range of FEV 1 values at baseline, all of which fell within normal limits. Other studies examining longitudinal changes in pulmonary function and EMGpara during acute exacerbations of lung disease (Murphy et al. 2011; Reilly et al. 2012) have the additional confounding influence of the metabolic load of acute illness and infection, making interpretation of relationships more challenging. These previous data show markedly larger changes in EMGpara than those seen in the present study, although the populations under investigation are substantially different. It is plausible that the relationship between airflow obstruction and EMGpara is curvilinear, and future studies could consider examining larger cohorts to allow detailed cross-sectional or longitudinal measurements to be made across the full spectrum of disease severity.
Linear mixed model analysis did not demonstrate a significant effect of changing IC on change in EMGpara, suggesting little contribution of lung hyperinflation to overall respiratory load. The known influence of increased lung volume on the length-tension characteristics of the respiratory muscles would suggest that it is likely that hyperinflation would have an influence on levels of NRD, and indeed, previous studies have demonstrated relationships between measures of end-expiratory lung volume and NRD Reilly et al. 2011) . The severity of hyperinflation reported in these studies was, however, much more pronounced (lowest IC values of ß44% predicted and 1.1 litre, respectively) than that observed in the present study, in which the median reduction in IC was only 245 ml, with all participants having normal lung function at baseline. Such modest changes in end-expiratory lung volume in the present study would most probably have resulted in pulmonary mechanics remaining within the linear portion of the respiratory system compliance curve, thus markedly greater levels of NRD and transpulmonary pressures would not have been required to achieve equivalent levels of tidal breathing. The parasternal intercostal muscles, although known to act in concert with the diaphragm (De Troyer & Estenne, 1984) and respond in a similar manner with regard to alterations in the respiratory load-capacity balance, do not show an identical activation pattern . Specifically, they experience less of a decrement in their mechanical advantage with increasing lung volume than does the diaphragm (Decramer & De Troyer, 1984) . Conversely, increases in operating lung volumes can have a beneficial effect in conditions of mild airflow obstruction, by increasing radial traction on the airways, increasing airway calibre (Briscoe & Dubois, 1958) and reducing airway resistance. These factors may combine to explain the lack of influence of changes in IC on EMGpara in the present study. It must also be recognized that the number of subjects within the present study somewhat limits the statistical power to interpret the relatively modest changes in lung volume elicited by the challenge test when incorporating multiple terms into the linear mixed model.
In conclusion, we have demonstrated methacholineinduced increases in neural drive to the parasternal intercostal muscles in adult subjects, the degree of which was influenced by the magnitude of airflow obstruction. Moderate changes in end-expiratory lung volume did not, in this study, influence levels of parasternal intercostal EMG activity.
